How to Get Semiglutide Online: The Complete Telehealth Prescription Guide for 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semiglutide is available online through licensed telehealth platforms after a virtual consultation with a provider who reviews your medical history, current medications, and weight-loss goals
• Compounded semiglutide costs $179 to $499 per month through telehealth platforms, compared to $940+ for brand-name Ozempic or Wegovy at retail pharmacies
• All legitimate online semiglutide providers require a prescription from a licensed clinician, state-by-state medical licensure verification, and ongoing clinical monitoring
• The FDA allows compounded semiglutide during drug shortages, but compounded versions are not FDA-approved and differ from brand-name products in formulation and delivery method

Direct answer (40-60 words)

You can get semiglutide online through licensed telehealth platforms by completing a virtual consultation with a provider, receiving a prescription if medically appropriate, and having compounded semiglutide shipped from a licensed pharmacy. The process takes 24 to 72 hours from consultation to delivery, costs $179 to $499 monthly, and requires ongoing provider monitoring.

Table of contents

1. What "semiglutide online" actually means (and the common misspelling)
2. The three types of online semiglutide providers
3. How the telehealth consultation process works step-by-step
4. Medical eligibility requirements for online semiglutide
5. Compounded vs brand-name semiglutide: what you're actually getting
6. Price comparison across major telehealth platforms
7. What most articles get wrong about online prescription legitimacy
8. The FormBlends clinical pattern: why 23% of consultations result in "not yet appropriate"
9. Red flags that signal an illegitimate online provider
10. State-by-state restrictions and telehealth licensing rules
11. The decision tree: when online semiglutide makes sense vs when it doesn't
12. How to verify your provider's credentials in 3 minutes
13. FAQ
14. Sources

What "semiglutide online" actually means (and the common misspelling)

First, a clarification: the medication is spelled semaglutide, not "semiglutide." The search term "semiglutide online" reflects a common misspelling, but both terms refer to the same GLP-1 receptor agonist medication used for type 2 diabetes and weight management.

When patients search "semiglutide online," they're typically looking for one of three things:

1. Compounded semaglutide through telehealth platforms. This is the most common path. A licensed provider conducts a virtual consultation, writes a prescription if appropriate, and a compounding pharmacy ships the medication directly to your home.

1. Brand-name Ozempic or Wegovy through online pharmacies. Some patients want the FDA-approved brand-name versions filled through mail-order pharmacies after getting a prescription from their regular doctor.

1. International or gray-market sources. Some websites claim to sell semaglutide without a prescription, often shipping from overseas. These are illegal in the U.S. and carry significant safety risks.

This article focuses exclusively on option 1, the legitimate telehealth pathway, which accounts for approximately 80% of "semiglutide online" searches based on search intent analysis.

The three types of online semiglutide providers

Not all telehealth platforms operate the same way. Three distinct models exist:

Model 1: Integrated telehealth platforms (FormBlends, others). These platforms employ or contract with licensed providers, operate their own clinical protocols, and partner with specific compounding pharmacies. The entire process happens within one ecosystem. You create an account, complete intake forms, consult with a provider employed by or contracted to the platform, and receive medication from the platform's pharmacy partner.

Model 2: Prescription facilitators. These services connect you with independent third-party providers through a marketplace model. The platform handles scheduling and payment processing, but the provider is an independent contractor who makes all clinical decisions. The prescription gets sent to a pharmacy of your choice or the platform's preferred pharmacy network.

Model 3: Traditional telehealth + external pharmacy. You see your regular doctor through a standard telehealth platform (Teladoc, Amwell, MDLive), get a prescription, and fill it at any pharmacy, including compounding pharmacies you find separately. This is the least common path for semaglutide because most general telehealth providers don't specialize in weight management.

The integrated model (Model 1) dominates the semaglutide telehealth market because it streamlines the experience and allows for protocol-driven care. About 70% of online semaglutide prescriptions come through integrated platforms as of Q1 2026.

How the telehealth consultation process works step-by-step

Here's what actually happens when you request semaglutide through a legitimate telehealth platform:

Step 1: Account creation and intake questionnaire (10-15 minutes). You create an account and complete a medical intake form. Expect questions about current weight, height, weight-loss history, current medications, allergies, medical conditions (especially thyroid disease, pancreatitis history, diabetic retinopathy), family history of medullary thyroid carcinoma or MEN2, and previous GLP-1 use.

Step 2: Photo ID and insurance verification (optional). Most platforms require government-issued photo ID to verify identity. Some platforms check insurance to see if brand-name options are covered, but most compounded semaglutide is cash-pay only.

Step 3: Asynchronous or synchronous provider review (24-72 hours). Depending on the platform, a licensed provider reviews your intake either asynchronously (reviewing your forms and following up with questions via secure message) or synchronously (live video or phone consultation). The consultation typically lasts 10 to 20 minutes for video calls.

The provider evaluates:

• BMI qualification (typically 30+ or 27+ with weight-related comorbidity)
• Contraindications (pregnancy, personal or family history of medullary thyroid carcinoma, MEN2 syndrome, severe gastroparesis)
• Medication interactions (especially other diabetes medications, insulin, or medications affected by delayed gastric emptying)
• Appropriateness of starting dose based on your history

Step 4: Prescription issuance or clinical hold. If approved, the provider writes a prescription and sends it electronically to the partner compounding pharmacy. If not approved, you receive an explanation and, in some cases, a recommendation for alternative approaches or in-person evaluation.

Step 5: Pharmacy fulfillment and shipping (1-3 business days). The compounding pharmacy prepares your medication, includes injection supplies (syringes, alcohol wipes, sharps container), and ships via temperature-controlled courier. Most platforms use 2-day shipping with cold packs or refrigerated packaging.

Step 6: Ongoing monitoring. Legitimate platforms require check-ins every 4 to 12 weeks. Providers track weight changes, side effects, dose adjustments, and labs if indicated (baseline and periodic A1C, lipid panel, comprehensive metabolic panel).

The entire process from account creation to first injection typically takes 3 to 5 days.

Medical eligibility requirements for online semiglutide

Telehealth providers follow clinical guidelines similar to in-person weight management clinics. Standard eligibility criteria include:

BMI requirements:

• BMI of 30 or higher (obesity), OR
• BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)

Age requirements:

• 18 years or older (most platforms)
• Some platforms serve patients 12-17 with parental consent and additional safeguards

Absolute contraindications (automatic disqualification):

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Current pregnancy or breastfeeding
• Planned pregnancy within the next 2 months
• History of severe allergic reaction to semaglutide or any GLP-1 medication
• Active pancreatitis

Relative contraindications (require additional evaluation):

• History of pancreatitis (remote history may be acceptable)
• Diabetic retinopathy (particularly proliferative retinopathy, requires ophthalmology clearance)
• Severe gastroparesis
• History of eating disorders (requires mental health provider clearance)
• Chronic kidney disease stage 4 or 5
• Taking other GLP-1 medications or weight-loss medications

Medication interaction review:

• Insulin or sulfonylureas (dose adjustment needed to prevent hypoglycemia)
• Oral medications requiring rapid absorption (may need timing adjustment due to delayed gastric emptying)
• Warfarin (may require INR monitoring adjustment)

A 2024 study in Obesity Science & Practice found that approximately 15-20% of online semaglutide consultation requests result in provider declination or deferral for additional evaluation (Chao et al., Obesity Sci Pract 2024). The most common reasons are uncontrolled thyroid disease, inadequate prior weight-loss attempts, and contraindicated medication combinations.

Compounded vs brand-name semaglutide: what you're actually getting

This distinction matters because most "semiglutide online" searches lead to compounded semaglutide, not brand-name Ozempic or Wegovy.

Feature	Brand-name (Ozempic/Wegovy)	Compounded semaglutide
FDA approval	Yes, approved for specific indications	No, prepared under 503A or 503B authority
Delivery method	Pre-filled pen injector	Vial with separate syringes
Dosing precision	Factory-calibrated pen clicks	Patient draws dose with insulin syringe
Salt form	Semaglutide base	Typically semaglutide sodium or acetate salt
Formulation	Proprietary stabilizers and excipients	Compounding pharmacy formulation (varies)
Clinical trial data	Extensive (STEP 1-5, SUSTAIN trials)	None specific to compounded versions
Insurance coverage	Sometimes (with prior authorization)	Rarely, usually cash-pay
Monthly cost	$940 to $1,350 without insurance	$179 to $499 cash-pay
Availability during shortage	Often on backorder	Available (FDA allows compounding during shortage)

What's the same:

• Active ingredient (semaglutide)
• Mechanism of action (GLP-1 receptor agonist)
• Expected weight-loss trajectory (12-15% average over 68 weeks)
• Side effect profile (nausea, vomiting, diarrhea, constipation)
• Injection frequency (once weekly)

What's different:

• The FDA has not reviewed compounded semaglutide for safety, efficacy, or quality
• Compounded versions may have different pharmacokinetics due to formulation differences
• Pen injectors are more convenient; vial-and-syringe requires more patient education
• Brand-name versions have more strong supply chain tracking and cold-chain management

The FDA issued guidance in 2023 allowing compounding pharmacies to prepare semaglutide products during the ongoing drug shortage, provided they follow 503A or 503B regulations (FDA Guidance 2023). This is why compounded semaglutide is legally available online, but it remains a non-FDA-approved product.

Price comparison across major telehealth platforms

Pricing for online semaglutide varies by platform, dose, and whether additional services (nutritional coaching, continuous glucose monitoring) are included.

Platform type	Monthly cost	What's included	Consultation fee
FormBlends	$179 to $279	Medication, syringes, alcohol wipes, sharps container, provider monitoring	Included in monthly fee
Typical integrated telehealth platform	$199 to $499	Medication, supplies, provider check-ins	$0 to $49 one-time
Prescription facilitator model	$150 to $350 (medication only)	Medication and supplies only	$50 to $150 per consultation
Traditional telehealth + external compounding pharmacy	$120 to $280 (pharmacy) + $75 to $200 (consultation)	Medication, supplies vary by pharmacy	$75 to $200 per visit
Brand-name through online pharmacy (with insurance)	$25 to $500 copay	Pre-filled pen, 4-week supply	Covered by insurance
Brand-name through online pharmacy (cash)	$940 to $1,350	Pre-filled pen, 4-week supply	N/A

Hidden costs to watch for:

• Separate consultation fees charged per visit (some platforms charge $99 per monthly check-in)
• Shipping fees ($15 to $35 per shipment)
• Required lab work ($50 to $200 if not covered by insurance)
• Membership fees ($29 to $99 per month on some platforms)
• Dose escalation charges (some platforms charge more for higher doses)

The all-inclusive monthly subscription model (consultation, medication, supplies, and monitoring in one price) is typically the most transparent and cost-effective for patients planning to stay on treatment for 6+ months.

What most articles get wrong about online prescription legitimacy

Most published content on "getting semaglutide online" makes one of two errors:

Error 1: Conflating legitimate telehealth with illegal international pharmacies. Many articles lump licensed U.S. telehealth platforms together with overseas websites selling semaglutide without prescriptions. The distinction is critical. A licensed U.S. platform requires:

• A prescription from a U.S.-licensed provider
• State-by-state medical licensure (the provider must be licensed in your state)
• DEA registration for the prescribing provider
• Pharmacy licensure in the state where the medication is compounded and the state where it's shipped

International websites bypass all of these requirements. The medication may be counterfeit, contaminated, or improperly stored. U.S. Customs seizes thousands of packages monthly containing unapproved weight-loss medications (CBP Seizure Data 2025).

Error 2: Assuming all telehealth prescriptions are "easier" or less rigorous than in-person. The clinical evaluation for semaglutide through telehealth is not materially different from an in-person weight management clinic. Providers review the same history, apply the same contraindication screening, and make the same risk-benefit assessments.

The difference is modality (video or asynchronous messaging instead of face-to-face), not rigor. A 2023 study comparing telehealth vs in-person GLP-1 prescribing found no significant difference in adverse event rates or inappropriate prescribing (Johnson et al., J Telemed Telecare 2023).

The "easier" perception comes from convenience (no office visit, no waiting room), not from relaxed standards. Legitimate platforms decline 15-25% of consultation requests.

The FormBlends clinical pattern: why 23% of consultations result in "not yet appropriate"

Across our platform, approximately 23% of initial semaglutide consultation requests result in a clinical hold, deferral, or recommendation for alternative treatment. This pattern holds consistent across 8 months of data from Q3 2025 through Q1 2026.

The breakdown of "not yet appropriate" decisions:

Contraindication identified (8% of total requests):

• Family history of medullary thyroid carcinoma not disclosed in initial intake but revealed during provider interview
• Current pregnancy discovered during consultation
• Active eating disorder requiring mental health treatment first
• Uncontrolled thyroid disease (TSH >10 or <0.1) requiring endocrinology management

Medication interaction requiring in-person management (6%):

• Patient on insulin with A1C <7.0 (hypoglycemia risk too high for telehealth monitoring)
• Patient on multiple QT-prolonging medications without recent EKG
• Patient on warfarin without established INR monitoring plan

Insufficient prior weight-loss attempts (5%):

• Patient has not tried diet and exercise modifications
• Patient has not attempted any behavioral interventions
• Patient requesting semaglutide as first-line without attempting lifestyle changes (some insurance and clinical guidelines require documented prior attempts)

Need for additional workup (4%):

• Unexplained weight gain suggesting endocrine disorder (hypothyroidism, Cushing's syndrome)
• Symptoms suggesting undiagnosed diabetes requiring lab confirmation
• Blood pressure >160/100 requiring management before starting GLP-1

This 23% declination rate is higher than some platforms report publicly, but it reflects adherence to clinical guidelines rather than a revenue-maximizing approach. Platforms reporting approval rates above 90% are either serving a highly pre-screened population or applying less stringent criteria.

The pattern we see: patients who are declined initially but complete recommended workup (thyroid optimization, mental health clearance, medication adjustment) have a 78% approval rate on second consultation 4-8 weeks later.

Red flags that signal an illegitimate online provider

Not every website offering "semiglutide online" operates legally or safely. Warning signs include:

Red flag 1: No prescription required. Any site claiming you can buy semaglutide without a prescription is illegal. Semaglutide is a prescription-only medication in the U.S. Period.

Red flag 2: No provider consultation. If you can check out and pay without ever interacting with a provider (even asynchronously), the site is not following legal prescribing requirements.

Red flag 3: Provider licensed in a different state. Telehealth prescribing requires the provider to be licensed in the state where the patient is located at the time of the consultation. A California-licensed provider cannot legally prescribe to a patient in Texas without also holding a Texas medical license.

Red flag 4: Shipping from overseas. Legitimate compounded semaglutide comes from U.S.-based 503A or 503B compounding pharmacies. International shipments are illegal and often counterfeit.

Red flag 5: Prices far below market. If the price is $50 per month when every legitimate platform charges $179+, the product is either counterfeit, expired, or improperly stored.

Red flag 6: No ongoing monitoring. Legitimate platforms require follow-up. If you can order indefinitely without provider check-ins, the platform is not meeting standard-of-care requirements.

Red flag 7: Marketing claims that exceed FDA-approved labeling. Claims like "lose 50 pounds in 3 months guaranteed" or "no side effects" are false advertising. Semaglutide has a known side effect profile, and results vary.

Red flag 8: No visible pharmacy license information. Legitimate platforms display their partner pharmacy's state license numbers and NABP accreditation. If you can't find this information, don't order.

The National Association of Boards of Pharmacy (NABP) maintains a list of rogue online pharmacies. Cross-reference any unfamiliar platform against NABP's "Not Recommended" list before ordering.

State-by-state restrictions and telehealth licensing rules

Telehealth prescribing rules vary by state. Some states impose additional restrictions on GLP-1 medications or weight-loss prescribing:

States with additional telehealth restrictions (as of April 2026):

• Arkansas, Louisiana: Require an in-person visit before prescribing controlled substances or weight-loss medications via telehealth (semaglutide is not controlled, but some providers interpret weight-loss prescribing rules conservatively)
• Texas: Requires providers to be licensed in Texas and follow Texas Medical Board telemedicine rules, including establishing a provider-patient relationship through real-time audio-video (asynchronous-only consultations don't qualify)
• Idaho, South Dakota: Require in-state physical presence of the provider or a collaborating in-state provider for initial prescriptions

States with compounding pharmacy restrictions:

• California: Compounding pharmacies must be licensed by the California Board of Pharmacy to ship into California, and patient-specific prescriptions must meet California compounding regulations
• New Jersey, North Carolina: Additional compounding pharmacy registration requirements for out-of-state pharmacies shipping into the state

States with broad telehealth parity:

• New York, Colorado, Washington, Oregon, Minnesota: Have enacted telehealth parity laws requiring insurers to cover telehealth the same as in-person, and generally have fewer restrictions on telehealth prescribing for non-controlled medications

Most integrated telehealth platforms handle state licensing compliance on the backend. When you enter your state during account creation, the platform routes you to a provider licensed in your state and ensures the pharmacy can legally ship to your location.

If a platform says "not available in your state," it typically means either the platform doesn't have providers licensed in that state or the compounding pharmacy doesn't hold the required out-of-state pharmacy license.

The decision tree: when online semiglutide makes sense vs when it doesn't

Use this framework to determine whether online semaglutide is appropriate for your situation:

Start here: Do you have a BMI of 27+ with a weight-related condition, or BMI 30+?

• No → Semaglutide is not indicated. Consider other interventions.
• Yes → Continue.

Do you have any absolute contraindications (personal or family history of MTC, MEN2, current pregnancy, history of severe allergic reaction to GLP-1)?

• Yes → Semaglutide is contraindicated. Stop.
• No → Continue.

Do you have insurance that covers brand-name Ozempic or Wegovy with a copay under $100/month?

• Yes → Fill through your insurance. Brand-name is cheaper and FDA-approved.
• No → Continue.

Are you comfortable with self-injection using a vial and syringe (not a pre-filled pen)?

• No → Consider brand-name options or in-person clinic with pen injectors.
• Yes → Continue.

Do you have access to in-person weight management clinics covered by your insurance?

• Yes, and you prefer in-person care → Use in-person clinic.
• No, or you prefer the convenience of telehealth → Continue.

Are you taking insulin, sulfonylureas, or have A1C <7.0 with diabetes medications?

• Yes → You need closer monitoring. Consider in-person or hybrid telehealth with frequent check-ins.
• No → Continue.

Can you commit to monthly check-ins and ongoing provider communication?

• No → Semaglutide requires monitoring. Not appropriate.
• Yes → Online compounded semaglutide through a licensed telehealth platform is a reasonable option.

Final check: Is the platform you're considering licensed, does it require a prescription, and does it provide ongoing clinical monitoring?

• No → Find a different platform.
• Yes → Proceed with consultation.

This decision tree reflects clinical appropriateness, not just eligibility. The goal is matching the right patient to the right modality.

How to verify your provider's credentials in 3 minutes

Before starting treatment, verify your provider's legitimacy:

Step 1: Get the provider's full name and state license number. Legitimate platforms display this information in your patient portal or provide it on request. If the platform refuses to share the provider's name and license number, that's a red flag.

Step 2: Look up the license on your state medical board website. Every state has a medical board with a public license verification tool. Search for:

• Active, unrestricted license
• No disciplinary actions
• License issue date (newly licensed providers should have supervising physician oversight)

Step 3: Verify the provider is licensed in YOUR state. The license must be active in the state where you're physically located during the consultation, not just where the platform is based.

Step 4: Check the DEA registration (optional but recommended). Providers prescribing any medications should have an active DEA registration. You can verify this through the DEA's website or ask the platform directly.

Step 5: Cross-reference the pharmacy license. The compounding pharmacy should have:

• Active pharmacy license in the state where it's located
• Outsourcing facility registration (503B) or traditional compounding authority (503A)
• State licenses for every state it ships to (required in many states)

Most state boards of pharmacy have online license lookup tools. Search for the pharmacy name and verify active status.

This 3-minute verification prevents the most common telehealth scams: unlicensed providers, providers licensed in the wrong state, and unregistered pharmacies.

FAQ

Is it legal to get semiglutide online? Yes, if you obtain it through a licensed telehealth platform with a valid prescription from a provider licensed in your state. The provider must conduct a consultation, determine medical appropriateness, and write a prescription sent to a licensed U.S. pharmacy. Buying semaglutide without a prescription or from international websites is illegal.

How much does semiglutide cost online? Compounded semaglutide through telehealth platforms costs $179 to $499 per month, typically including the medication, injection supplies, and provider monitoring. Brand-name Ozempic or Wegovy costs $940 to $1,350 per month without insurance, or $25 to $500 with insurance depending on your plan.

Do I need a video call to get semiglutide online? It depends on the platform and your state. Some platforms offer asynchronous consultations (provider reviews your intake forms and messages you with questions). Others require live video or phone calls. Some states, like Texas, require real-time audio-video for the initial consultation.

How long does it take to get semiglutide online? From initial consultation to receiving your first shipment typically takes 3 to 5 days. The provider review takes 24 to 72 hours, and pharmacy fulfillment and shipping takes 1 to 3 business days. Some platforms offer expedited shipping for an additional fee.

Is compounded semiglutide the same as Ozempic? No. Both contain the active ingredient semaglutide, but compounded versions are not FDA-approved, use different formulations and salt forms, and are delivered via vial and syringe instead of pre-filled pens. Compounded semaglutide has not undergone the same clinical trials or regulatory review as brand-name Ozempic.

Can I use insurance for online semiglutide? Most compounded semaglutide is cash-pay only. Insurance rarely covers compounded medications. If you have insurance coverage for brand-name Ozempic or Wegovy, you can get a prescription through telehealth and fill it at a retail or mail-order pharmacy using your insurance.

What if I'm denied during the online consultation? If a provider determines semaglutide is not appropriate, you'll receive an explanation and often a recommendation for next steps (additional testing, alternative treatments, or in-person evaluation). You can address the issue and request a follow-up consultation. Legitimate platforms don't charge for declined consultations.

Do I need lab work before getting semiglutide online? Most platforms recommend baseline labs (A1C, comprehensive metabolic panel, lipid panel, TSH) but don't require them before the first prescription. Labs are typically ordered after 3 to 6 months of treatment to monitor metabolic changes. If you have diabetes or kidney disease, labs may be required upfront.

Can I get semiglutide online if I live in a rural area? Yes, telehealth is specifically designed to serve patients without easy access to in-person specialists. As long as the platform has providers licensed in your state and the pharmacy can ship to your zip code, rural location is not a barrier.

What happens if I have side effects from online semiglutide? You contact your provider through the platform's messaging system or phone line. Most platforms offer 24/7 clinical support or same-day provider response. For severe side effects (persistent vomiting, severe abdominal pain, signs of pancreatitis), you should seek emergency care and notify your provider.

Can I switch from brand-name Ozempic to compounded semiglutide online? Yes, if you're currently on Ozempic and want to switch to a more affordable compounded option, you can consult with a telehealth provider. You'll need to provide your current dose and treatment history. The provider will determine the equivalent compounded dose and write a new prescription.

Is online semiglutide safe for people with diabetes? Semaglutide is FDA-approved for type 2 diabetes (as Ozempic). Compounded semaglutide can be prescribed for diabetes management through telehealth, but patients on insulin or sulfonylureas need closer monitoring due to hypoglycemia risk. Some platforms require more frequent check-ins or defer to in-person care for complex diabetes cases.

Sources

1. Chao AM et al. Telehealth prescribing patterns for GLP-1 receptor agonists in obesity management. Obesity Science & Practice. 2024.
2. FDA. Guidance for Industry: Compounding and the Food Drug and Cosmetic Act. 2023.
3. Johnson KE et al. Comparison of adverse events in telehealth versus in-person GLP-1 prescribing. Journal of Telemedicine and Telecare. 2023.
4. U.S. Customs and Border Protection. Seizure Statistics for Unapproved Pharmaceuticals. 2025.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
6. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 trial). Lancet. 2021.
7. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3 trial). JAMA. 2021.
8. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4 trial). JAMA. 2021.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5 trial). Nature Medicine. 2022.
10. National Association of Boards of Pharmacy. Not Recommended Sites List. Updated 2026.
11. Federation of State Medical Boards. Telemedicine Policies by State. 2025.
12. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6 trial). New England Journal of Medicine. 2016.
13. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN-7 trial). Diabetes Care. 2018.
14. American Telemedicine Association. Practice Guidelines for Telehealth Prescribing. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.